For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Site Menu
Buscar Close Search
Buscar Close Search
Profile Picture for Aronin

Neil Aronin, MD

Professor of Department of Medicine and the RNA Therapeutics Institute, Division Chief of Endocrinology, Higgins Family Professor of Neuroscience

Website

Research Focus - Therapeutic Development in Neurodegenerative Diseases

  • Developing therapeutics for Huntington’s disease using
    • RNA interference
    • genome editing 
  • Collaboration with University of Texas, San Antonio to investigate genetic mutations and susceptibility loci in pheochromocytoma

Representative Publications

  • Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42(3):229-233. Read Publication
More Publications

In the News

  • Atalanta Therapeutics founded by UMass Medical School and three faculty members
    Research News
    Jan 12, 2021

    Atalanta Therapeutics founded by UMass Medical School and three faculty members

    Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech.

    Read more
  • Yasaman Gholamalipour awarded fellowship by Huntington’s Disease Society of America
    Research News
    Jun 23, 2020

    Yasaman Gholamalipour awarded fellowship by Huntington’s Disease Society of America

    UMass Medical School postdoctoral associate Yasaman Gholamalipour, PhD, was awarded the Huntington’s Disease Society of America Berman-Topper Family HD Career Development Fellowship for 2020.

    Read more
  • UMMS scientists mark progress on Huntington’s disease research
    Research News
    Jul 17, 2019

    UMMS scientists mark progress on Huntington’s disease research

    Neil Aronin, MD, led an afternoon of presentations detailing advances made by scientists at UMass Medical School in the quest to find a treatment for Huntington’s disease. CHDI Foundation President Robi Blumenstein accepted a plaque in recognition of the foundation’s $13 million in support of Huntington’s research at the medical school.

    Read more